City

Clinical trials near Toronto, Canada

Active studies with a listed research site in Toronto, Canada.

53active studies

22recruiting now

30countries represented

1,498largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowNot applicable

Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control

Diabetes Mellitus, Type 2, ObesityCondition

Early (7:00 - 16:00) TRE, Mid (9:30 - 18:30) TRETreatment

Canada1 locations

University of TorontoSponsor

Updated 2026-06-30 · NCT06118931See eligibility →

Recruiting nowPhase 4

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Kidney Disease, Chronic, DiabetesCondition

Semaglutide PenTreatment

Canada2 locations

Unity Health TorontoSponsor

Updated 2026-06-26 · NCT07017270See eligibility →

Recruiting nowNot applicable

Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients

ObesityCondition

Head position for face mask ventilation during induction supine, Head position for face mask ventilation during induction head elevatedTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-06-17 · NCT06305273See eligibility →

Recruiting nowPhase 2

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Diabetic Kidney Disease, Type 1 DiabetesCondition

Semaglutide, PlaceboTreatment

Canada, United States4 locations

University of WashingtonSponsor

Updated 2026-06-02 · NCT05822609See eligibility →

Recruiting nowPhase 2

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Kidney Transplant RecipientsCondition

Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mLTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2026-05-01 · NCT05938712See eligibility →

Recruiting nowPhase 4

Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

Intellectual Disability, Developmental DisabilityCondition

Metformin, PlaceboTreatment

Canada1 locations

Centre for Addiction and Mental HealthSponsor

Updated 2026-03-31 · NCT05744479See eligibility →

Recruiting nowNot applicable

The Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors

Dairy Consumption, Metabolic HealthCondition

Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study), Dairy (short-term study)Treatment

Canada2 locations

University of TorontoSponsor

Updated 2026-03-05 · NCT06879652See eligibility →

Recruiting nowNot applicable

Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial

Type 2 Diabetes, Overweight (BMI > 25)Condition

Time-restricted eating, Standard lifestyleTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-02-11 · NCT07272460See eligibility →

Recruiting nowPhase 3

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Obesity (Disorder), Weight ChangeCondition

Gradual dose reduction of semaglutide, Abrupt cessation of semaglutideTreatment

Canada1 locations

Mount Sinai Hospital, CanadaSponsor

Updated 2026-02-11 · NCT07294950See eligibility →

Recruiting nowNot applicable

Evaluation of the SickKids Team Obesity Management Program

ObesityCondition

STOMP ClinicTreatment

Canada1 locations

The Hospital for Sick ChildrenSponsor

Updated 2022-09-13 · NCT01515904See eligibility →

Recruiting nowNot applicable

TARGet Kids!: Measuring Nutrition in Young Preschool Children in the Primary Care Practice Setting

Nutritional Disorders, ObesityCondition

Intervention not listedTreatment

Canada3 locations

The Hospital for Sick ChildrenSponsor

Updated 2021-11-17 · NCT01869530See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonNot applicable

IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition

Overweight (BMI > 25), Males and FemalesCondition

Milk, Greek YogurtTreatment

Canada1 locations

York UniversitySponsor

Updated 2026-04-07 · NCT07513987See eligibility →

Opening soonPhase 2, Phase 3

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Kidney Transplant RecipientCondition

Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus]Treatment

Canada2 locations

University Health Network, TorontoSponsor

Updated 2025-04-06 · NCT06913023See eligibility →

Invitation onlyPhase 4

Semaglutide vs Sitagliptin

Liver Transplant; Complications, Diabetes MellitusCondition

Semaglutide Treatment, Sitagliptin 100mgTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2026-04-06 · NCT05195944See eligibility →

Active, not recruitingPhase 3

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Argentina, Bulgaria188 locations

PfizerSponsor

Updated 2026-09-08 · NCT07400653See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

Breast Cancer WEight Loss Study (BWEL Study)

Breast Ductal Carcinoma In Situ, Invasive Breast CarcinomaCondition

Health Education Program, Weight Loss InterventionTreatment

Canada, Guam1,498 locations

Alliance for Clinical Trials in OncologySponsor

Updated 2026-09-02 · NCT02750826See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Semaglutide, Placebo (semaglutide)Treatment

Brazil, Bulgaria229 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT03811561See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients

Obesity, Morbid, Eating Disorder SymptomCondition

Mindfulness Based Eating and Awareness TrainingTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2026-06-11 · NCT03488966See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingPhase 4

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

ObesityCondition

SemaglutideTreatment

Belgium, Canada93 locations

Novo Nordisk A/SSponsor

Updated 2026-06-02 · NCT06571383See eligibility →

Active, not recruitingNot applicable

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Schizophrenia Spectrum DisordersCondition

Semaglutide, PlaceboTreatment

Canada1 locations

Centre for Addiction and Mental HealthSponsor

Updated 2026-05-27 · NCT05333003See eligibility →

Active, not recruitingNot applicable

MagDI Canada Study

Obesity, Type 2 DiabetesCondition

Magnet System, DI BiofragmentableTreatment

Canada3 locations

GT Metabolic Solutions, Inc.Sponsor

Updated 2026-05-20 · NCT06467955See eligibility →

Active, not recruitingPhase 2

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Overweight, ObesityCondition

Tirzepatide, PlaceboTreatment

Austria, Canada27 locations

Eli Lilly and CompanySponsor

Updated 2026-05-08 · NCT05536804See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2Condition

Retatrutide, SemaglutideTreatment

Argentina, Canada77 locations

Eli Lilly and CompanySponsor

Updated 2026-04-13 · NCT06260722See eligibility →

Active, not recruitingNot applicable

Association of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2

Apnea, Obstructive Sleep, ObesityCondition

Bioelectrical Impedance Analysis (BIA)Treatment

Canada1 locations

Samuel Lunenfeld Research Institute, Mount Sinai HospitalSponsor

Updated 2026-04-06 · NCT04187612See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

ObesityCondition

Retatrutide, PlaceboTreatment

Canada, United Kingdom53 locations

Eli Lilly and CompanySponsor

Updated 2026-03-03 · NCT06859268See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 2

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Diabetes Mellitus, Type 2, Diabetic Peripheral NeuropathyCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Canada, Denmark54 locations

Novo Nordisk A/SSponsor

Updated 2025-12-05 · NCT06797869See eligibility →

Active, not recruitingNot applicable

The Semaglutide Study

FastingCondition

Gastric UltrasoundTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2025-11-20 · NCT06420739See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

Active, not recruitingPhase 4

The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.

Ulcer, Gastric, Obesity, MorbidCondition

Indocyanine green, Stryker 1688 AIM systemTreatment

Canada1 locations

University Health Network, TorontoSponsor

Updated 2025-10-16 · NCT06002906See eligibility →

Active, not recruitingNot applicable

Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk

Diabetes, PrediabetesCondition

Intervention not listedTreatment

Canada1 locations

John SievenpiperSponsor

Updated 2025-09-30 · NCT02037321See eligibility →

Active, not recruitingNot applicable

The Effects of Long-term Consumption of Full-fat Dairy Products on Satiety, Body Weight and Glycemic Control

Overweight or Obesity, Body WeightCondition

Dairy-based commercially available food products, Restrictive EatingTreatment

Canada2 locations

University of TorontoSponsor

Updated 2025-03-28 · NCT04399460See eligibility →

Active, not recruitingNot applicable

Fit-for-Fertility Multicenter Randomized Controlled Trial

Obesity, Infertility, FemaleCondition

Fit-For-Fertility program, Standard of careTreatment

Canada5 locations

Université de SherbrookeSponsor

Updated 2025-03-19 · NCT03908099See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Toronto, Canada

Current studies

Related cities